U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17NO3.ClH
Molecular Weight 307.772
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORMORPHINE HYDROCHLORIDE

SMILES

Cl.O[C@H]1C=C[C@H]2[C@H]3CC4=C5C(O[C@@H]1[C@@]25CCN3)=C(O)C=C4

InChI

InChIKey=HQNHDHNPDOTERW-VIGPQYPBSA-N
InChI=1S/C16H17NO3.ClH/c18-11-3-1-8-7-10-9-2-4-12(19)15-16(9,5-6-17-10)13(8)14(11)20-15;/h1-4,9-10,12,15,17-19H,5-7H2;1H/t9-,10+,12-,15-,16-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H17NO3
Molecular Weight 271.3111
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Normorphine is an opiate analog, specifically the N-demethylated derivative of morphine. It was first described in the 1953 as part of an effort to characterize N-substituted morphine analogs. Normorphine has relatively little opioid activity, but it is a useful intermediate for the production of more potent morphine analogs. It is also a major metabolite of morphine.

Originator

Curator's Comment: # Merck

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35372|||G8XRH8|||Q5TDA1|||Q9UN57
Gene ID: 4988.0
Gene Symbol: OPRM1
Target Organism: Homo sapiens (Human)
0.061 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
41 nM
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
65 nM
50 mg 4 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
191 nM × h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9 nM × h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
220 nM × h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
257 nM × h
50 mg 4 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.8 h
50 mg 4 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NORMORPHINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
PubMed

PubMed

TitleDatePubMed
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
1998-03
Normorphine, a neurotoxic metabolite?
1990-03-24
Patents

Sample Use Guides

Normorphine hydrochloride was administered as a subcutaneous injection to male adult white volunteers as either a single 30 mg/kg dose or seven doses of 9 or 10 mg
Route of Administration: Parenteral
μ-Opioid receptor (MOR) expressing 293T cells were homogenized in 5 mM Tris, 2 mM EDTA, pH 7.4 and centrifuged to extract the cell pellet. The pellet was resuspended in 50 mM of potassium phosphate buffer, pH 7.4. 20 micro-g of membrane protein was mixed with 0.1 - 1 nM of 3H-naloxone, 100 micro-M GTP and various concentrations of normorphine. Samples were incubated for 3 hours, then filtered through a glass fiber filter before liquid scintillation counting. The radioligand binding assay determined the initial affinity of normorphine for the μ-opioid receptor; a Ki of 0.063 μM was reported.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:50 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:50 GMT 2025
Record UNII
069LMC1L4O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NORMORPHINE HYDROCHLORIDE
MI  
Common Name English
NORMORPHINE HYDROCHLORIDE [MI]
Preferred Name English
MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-, HYDROCHLORIDE (1:1), (5.ALPHA.,6.ALPHA.)
Systematic Name English
(5.ALPHA.,6.ALPHA.)-7,8-DIDEHYDRO-4,5-EPOXYMORPHINAN-3,6-DIOL HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
CAS
3372-02-9
Created by admin on Mon Mar 31 17:59:51 GMT 2025 , Edited by admin on Mon Mar 31 17:59:51 GMT 2025
PRIMARY
MERCK INDEX
m8070
Created by admin on Mon Mar 31 17:59:51 GMT 2025 , Edited by admin on Mon Mar 31 17:59:51 GMT 2025
PRIMARY Merck Index
FDA UNII
069LMC1L4O
Created by admin on Mon Mar 31 17:59:51 GMT 2025 , Edited by admin on Mon Mar 31 17:59:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID6048915
Created by admin on Mon Mar 31 17:59:51 GMT 2025 , Edited by admin on Mon Mar 31 17:59:51 GMT 2025
PRIMARY
ECHA (EC/EINECS)
222-152-9
Created by admin on Mon Mar 31 17:59:51 GMT 2025 , Edited by admin on Mon Mar 31 17:59:51 GMT 2025
PRIMARY
PUBCHEM
21124389
Created by admin on Mon Mar 31 17:59:51 GMT 2025 , Edited by admin on Mon Mar 31 17:59:51 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY